Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnostics

10 Dec 2024

Abstract excerpt

BACKGROUND: Poly (ADP ribose) polymerase inhibitors (PARPis) are a treatment option for patients with advanced high-grade serous or endometrioid ovarian carcinoma (OC). Recent guidelines have clarified how homologous recombination deficiency (HRD) may influence treatment decision-making in this setting. As a result, numerous companion diagnostic assays (CDx) have been developed to identify HRD. However, the...

Topics

Join the communities discussing this publication.

DNA Repair Mechanisms
Ovarian cancer diagnosis and treatment
PARP inhibition in cancer therapy

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 39693891
DOI: 10.1016/j.ejca.2024.115169

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnosticsPMID 39693891Read ↗

Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical PerspectivesSemantic proximity Read ↗

In-house homologous recombination deficiency testing in ovarian cancer: a multi-institutional Italian pilot studySemantic proximity Read ↗

Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer, Part 1: Technical ConsiderationsSemantic proximity Read ↗

Homologous Recombination Deficiency in Ovarian and Breast Cancers: Biomarkers, Diagnosis and TreatmentSemantic proximity Read ↗

Homologous Recombination Deficiency in Ovarian Cancer: from the Biological Rationale to Current Diagnostic ApproachesSemantic proximity Read ↗

Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP InhibitorsSemantic proximity Read ↗

How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literatureSemantic proximity Read ↗

Unraveling Homologous Recombination Deficiency in Ovarian Cancer: A Review of Currently Available Testing PlatformsSemantic proximity Read ↗

A Benchmark of In-House Homologous Recombination Repair Deficiency Testing Solutions for High-Grade Serous Ovarian Cancer DiagnosisSemantic proximity Read ↗

The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?Semantic proximity Read ↗

Limitations of homologous recombination status testing and poly (ADP-ribose) polymerase inhibitor treatment in the current management of ovarian cancerSemantic proximity Read ↗

Analysis of 20 Independently Performed Assays to Measure Homologous Recombination Deficiency (HRD) in Ovarian Cancer: Findings From the Friends' HRD Harmonization ProjectSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.